Abdominal Obesity and Cardiovascular Disease: Is Inflammation the Missing Link?

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 642-652

  Després, Jean Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; BODY FAT DISTRIBUTION; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; ENERGY BALANCE; FAMILY HISTORY; HUMAN; HYPERPLASIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MORPHOLOGY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING; WAIST CIRCUMFERENCE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; OBESITY, ABDOMINAL; RISK FACTORS; SURVIVAL RATE;

EID: 84869084160     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.06.004     Document Type: Review

References (107)

1. Cullen P., Schulte H., Assmann G. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur Heart J 1998, 19:1632-1641.
2. Kannel W.B., Dawber T.R., Friedman G.D., Glennon W.E., McNamara P.M. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study. Ann Intern Med 1964, 61:888-899.
3. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996, 94:273-278.
4. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
5. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823-2828.
6. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
7. Assmann G., Schulte H., Cullen P., Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 2007, 37:925-932.
8. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
9. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356:2388-2398.
10. Manuel D.G., Leung M., Nguyen K., Tanuseputro P., Johansen H. Burden of cardiovascular disease in Canada. Can J Cardiol 2003, 19:997-1004.
11. Mozaffarian D. Achieving cardiovascular health: a bleak outlook or tremendous potential?. J Am Coll Cardiol 2011, 57:1697-1699.
12. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
13. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
14. Onysko J., Maxwell C., Eliasziw M., et al. Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension 2006, 48:853-860.
15. James W.P. The epidemiology of obesity: the size of the problem. J Intern Med 2008, 263:336-352.
16. Poston W.S., Foreyt J.P. Obesity is an environmental issue. Atherosclerosis 1999, 146:201-209.
17. Ohinmaa A., Jacobs P., Simpson S., Johnson J.A. The projection of prevalence and cost of diabetes in Canada: 2000 to 2016. Can J Diabetes 2004, 28:116-123.
18. Riediger N.D., Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ 2011, 183:E1127-E1134.
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
20. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
21. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
22. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442-443.
23. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9:237-252.
24. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
25. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
26. Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961-967.
27. Cartier A., Lemieux I., Alméras N., Bergeron J., Després J.P. Increased global inflammation score among men with the metabolic syndrome: importance of visceral obesity [abstract]. Obes Res 2003, 11:A39.
28. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812-819.
29. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
30. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112:666-673.
31. McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabet Care 2005, 28:385-390.
32. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
33. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132.
34. Després J.P. Is visceral obesity the cause of the metabolic syndrome?. Ann Med 2006, 38:52-63.
35. Després J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
36. Després J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
37. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
38. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
39. Després J.P., Poirier P., Bergeron J., et al. From individual risk factors to the metabolic syndrome to global cardiometabolic risk. Eur Heart J 2008, 10:B24-B33.
40. Després J.P., Cartier A., CÔté M., Arsenault B.J. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 2008, 40:514-523.
41. Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007, 92:396-398.
42. Gale E.A. The myth of the metabolic syndrome. Diabetologia 2005, 48:1679-1683.
43. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
44. Lamarche B., Tchernof A., Mauriège P., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955-1961.
45. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
46. Spranger J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
47. Leiter L.A., Fitchett D.H., Gilbert R.E., et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol 2011, 27:e1-e33.
48. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men?. Circulation 2000, 102:179-184.
49. Lemieux I., Poirier P., Bergeron J., et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?. Can J Cardiol 2007, 23:23B-31B.
50. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
51. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65:S253-S259.
52. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
53. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-II10.
54. Tracy R.P. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999, 10:435-441.
55. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001, 47:403-411.
56. Ridker P.M. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003, 108:e81-e85.
57. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
58. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
59. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
60. Ridker P.M., Wilson P.W., Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004, 109:2818-2825.
61. Lavie C.J., Milani R.V., Verma A., O'Keefe J.H. C-reactive protein and cardiovascular diseases-is it ready for primetime?. Am J Med Sci 2009, 338:486-492.
62. Buckley D.I., Fu R., Freeman M., Rogers K., Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:483-495.
63. Bisoendial R.J., Kastelein J.J., Stroes E.S. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007, 195:e10-e18.
64. Pepys M.B. CRP or not CRP?. That is the question. Arterioscler Thromb Vasc Biol 2005, 25:1091-1094.
65. Després J.P. Inflammation and cardiovascular disease: is abdominal obesity the missing link?. Int J Obes Relat Metab Disord 2003, 27(suppl 3):S22-S24.
66. Castell J.V., Gomez-Lechon M.J., David M., et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
67. Baumann H., Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990, 7:147-159.
68. Cartier A., CÔté M., Lemieux I., et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity?. Am J Clin Nutr 2009, 89:1307-1314.
69. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005, 69:29-35.
70. Wormser D., Kaptoge S., Di Angelantonio E., et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011, 377:1085-1095.
71. Messier V., Karelis A.D., Prud'homme D., et al. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity (Silver Spring) 2010, 18:911-917.
72. Wildman R.P., Muntner P., Reynolds K., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
73. Ruderman N., Chisholm D., Pi-Sunyer X., Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998, 47:699-713.
74. Després J.P., Moorjani S., Ferland M., et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis 1989, 9:203-210.
75. Després J.P., Nadeau A., Tremblay A., et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989, 38:304-309.
76. Pouliot M.C., Després J.P., Nadeau A., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992, 41:826-834.
77. Arner E., Westermark P.O., Spalding K.L., et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 2010, 59:105-109.
78. Hoffstedt J., Arner E., Wahrenberg H., et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia 2010, 53:2496-2503.
79. Spalding K.L., Arner E., Westermark P.O., et al. Dynamics of fat cell turnover in humans. Nature 2008, 453:783-787.
80. Kirtland J., Gurr M.I. Adipose tissue cellularity: a review. 2. The relationship between cellularity and obesity. Int J Obes 1979, 3:15-55.
81. Björntorp P., Bengtsson C., Blohme G., et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971, 20:927-935.
82. Björntorp P., Sjöström L. Number and size of adipose tissue fat cells in relation to metabolism in human obesity. Metabolism 1971, 20:703-713.
83. Hirsch J., Knittle J.L., Salans L.B. Cell lipid content and cell number in obese and nonobese human adipose tissue. J Clin Invest 1966, 45:1023.
84. Krotkiewski M., Björntorp P., Sjöström L., Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983, 72:1150-1162.
85. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
86. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788.
87. Kim J.Y., van de Wall E., Laplante M., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007, 117:2621-2637.
88. Britton K.A., Fox C.S. Ectopic fat depots and cardiovascular disease. Circulation 2011, 124:e837-e841.
89. Furnsinn C., Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002, 45:1211-1223.
90. Giannini S., Serio M., Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004, 27:982-991.
91. Yang X., Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer?. Diabetologia 2007, 50:1127-1139.
92. Bertrand O.F., Poirier P., Rodés-Cabau J., et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 2010, 211:565-573.
93. Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009, 20:477-483.
94. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791.
95. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
96. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011, 342:d1309.
97. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
98. Björntorp P., Carlgren G., Isaksson B., et al. Effect of an energy-reduced dietary regimen in relation to adipose tissue cellularity in obese women. Am J Clin Nutr 1975, 28:445-452.
99. Borel A.L., Nazare J.A., Smith J., et al. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obesity (Silver Spring) 2012, 20:1223-1233.
100. Ross R., Dagnone D., Jones P.J., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000, 133:92-103.
101. Després J.P., Ross R., Boka G., Alméras N., Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009, 29:416-423.
102. Vitola B.E., Deivanayagam S., Stein R.I., et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring) 2009, 17:1744-1748.
103. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002, 105:564-569.
104. Selvin E., Paynter N.P., Erlinger T.P. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31-39.
105. Ross R., Bradshaw A.J. The future of obesity reduction: beyond weight loss. Nat Rev Endocrinol 2009, 5:319-325.
106. Després J.P., Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993, 6:137-159.
107. Paré A., Dumont M., Lemieux I., et al. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?. Obes Res 2001, 9:526-534.